Stichwortverzeichnis

A

Abhangigkeit 20 abstrakte Denkschwache 42 Abstraktionsvermogen 47 Affektinkontinenz 38 Mfekdabilitat 38 Agranulozytose 122 Akathisie 16, 25 Akutphase 99 Alkoholabhangigkeit 18 Alogie 11 AMDP-Schema 31, 32, 36 Angst-Gliicks-Psychose 24 Angststorungen 54 antipsychotische Wirkung 92 Arbeitsgemeinschaft fur Methodik

und Dokumentation in der Psychiatrie (AMDP) 32

Arbeitstherapie 85 Arzneimittelregresse 103 Atiopathogenese der Schizophrenie

76 Auffalligkeiten der Psychomotorik 39 Auffassungsstorungen 47 Aufklarung 121 Aufteilung der Schizophrenien nach

K. Leonhard 40

B

Basal-Ganglien 77 Basisstorungen 48 Behandlungskosten 134 Behandlungsstrategien 86 Benzodiazepin 20, 109 Benzodiazepinabhangigkeit 9 berufliche Rehabilitation 132 Beschaftigungstherapie 85 Betreuungsgutachten 119 bildgebende Verfahren 77 Biperiden 1 19 Blutbildkontrollen 132

c Carbamazepin 92, 129 Clozapin 16, 25, 27, 63, 92 Compliance 98, 99

o Defektsyndrom 22, 48 Denkstorungen

- formale 36, 42 - inhaldiche 36, 37

Denkzerfahrenheit 42 Depersonalisation 38 Depotmedikation 98

135

Stichworrverzeichnis

Derealisation 38 desorganisierte Sprechweise 11 desorganisierter Typus 43 diagnostische Zuordnung 64 Doctor Shopping 122 Doxepin 25 Drehtiirpsychiatrie 21 DSM-IV 11, 12, 64 ff DSM-IV: Achsen 54

E

Elektrokonvulsionsbehandlung 45, 129

Entwicklungsdauer von Neuroleptika 97

Entwicklungsstorung 11, 30 EPS, extrapyramidal-motorische

Nebenwirkungen 89, 94, 128, 133

Erhaltungsphase 99 Erholungsphase 131 erregtc Form einer Kataphasie 44

F

Familientherapie 85, 86 flacher Affekt 1 1 Flupentixol 109 Fluspirilen 10 formale Denkstorungen 36, 42 Fremd- und Eigenbeurteilungsskalen

29 Frontalhirn 77 Friihdyskinesien 25 Friiherkennung 101 Friihrezidiv 129 funktionclle bildgebcnde Verfahren 76 Furchenrelief 77

136

G

genetische Belastung 79 Gesetze und Rechtsnormen beim

Umgang mit schizophrenen Patienten 1 1 8

gestorrc Kognition 47 Gruppentherapie 86 Grundstorungen 48

H

Halluzinationen 11, 38 Haloperidol 97 Hemispharenasymmetrie 77 hirnanatomische Auffalligkeiten 77

I

iatrogene Spatschaden 9 ICD-I0 12, 64 ff iktogenes Risiko 27 Intelligenzminderung 47 Inzidenz 17

K

katatone Schizophrenie 68 katatoner Typus 13 kognitive Leistungen 86 Kosten 134

- direkte 134 - indirekte 134

Krampf 119 Krankheitseinsicht 36, 116 Krankhcitsgefiihl 36 Kunstfehlcrprozesse 10

L

Landeskrankenhaus 23 Langzeitbehandlung mit Depot­

Neuroleptika 24

Lebenszeitpravalenz 17 Leitsymptome 46 Leisrungseinbu/Sen 11 Lithium 88, 92 Lorazepam 81, 91, 92

M

malignes neuroleptisches Syndrom 129 Manie 88 Medikamentenlehre 103 medizinische Rehabilitation 132 Melperon 84 Minussymptomatik 16, 52 Mischpsychosen 51 Motilitatspsychose nach K. Leonhard

16 Murismus 16

N

Negativ- oder Minussymptome 48 Negativsymptomatik 22, 63 Neuroleptika 25, 45, 93

- atypische 45 - niederpotente 25, 45 - hochpotente 25, 27, 98

Neurose 54 Nikotinkonsum 101 Non-Compliance 63, 99

o Olanzapin 16, 45, 75, 95, 96, 97,

109, 116

p

paranoider Typus 105 Parathymie 38 Perazin 92 PET-Untersuchungen (Positronen­

Emissions-Tomographie) 76

Srichworrverzeichn.is

Pflichtfragen 32 Phenothiazine 132 Plussymptomatik 84 postschizophrene Depression 68 Pragnanztypen 10, 69 Pravalenzdaten bei Schizophrenie 17 Primarpersonlichkeit 28 Prodromi 52 Prognose 18, 20, 21, 46, 48, 49,

50, 63, 68, 84, 93, 117, 123, 131, 134

Prognoseentwicklung 20 Promethazin 127 Propranolol 127 psychiatrische Untersuchung 29 psychischer Befund 28, 32 psychopathologischer Befund 28, 32 Psychose 54, 64

- zykloide 16 - paranoid-halluzinatorische 109 - schizophrene 18

Punktpravalenz 17

Q Qualitatszirkel 103

R

Rechtsnormen 119 Reintegration 62 residualer Typus 73 Residualsymptom 48 Rezeptorprofile 96 Risikogruppen 18 Risperidon 16, 62, 63, 84, 95, 96,

102, 109

s Schizomanie 27, 129

137

Stichworrverzeichnis

Schizophasie 45 schizophrenes Residuum 68 Schizophrenia simplex 68 Schizophrenien

- sonstige 68 - systematische 40 - unsystematische 40

sekundares Suchtverhalten 18 Serotonin-Wiederaufnahmehemmer

119 Sertindol 43, 45, 102 soziale Isolation 20 sozialer Rtickzug 16 Spatdyskinesien 10, 25, 27, 92,

97, 98, 100, 121, 133 SPECT- (Single-Photon-Emissions­

Computertomographie) Unter­suchungen 76

Sport- und Bewegungstherapie 86, 87

Stabilisierungsphase 99, 131 Storungen

- affektive 11, 38, 46, 63, 90 - der Kognition 46 - der Motorik 46 - schizoaffektive 11, 23, 89 - schizotype 90

Suchtproblematik 101 Suizide 18 Suizidpravention 122 Suizidrisiko 19, 123 Sulpirid 74 Symptome

- charakteristische 11 - ersten und zweiten Ranges 50 - negative 11

138

T

Tachykardie 92 Talk-Down 31 tardive Dyskinesien 9, 27, 132 Teilleistungsschwachen 47 Temporallappen 77 Tiapridex 27

U

undifferenzierte Schizophrenie 68 undifferenzierter Typus 60, 62, 83 unerwtinschte Arzneimittelwirkungen

25, 27, 100

v Valproinsaure 92, 129 vegetative Storungen 32 Ventrikelsystem 77 Veranderungen der Personlichkeit 21 Verhalten

- desorganisiertes 11 - katatones 11

Verhaltensbeschreibung 28 Verlaufsbilder 67 Vulnerabilitat 79

W

Wahn 11, 37 wahnhafte Storung 113 Wahnphanomene 38 Willensschwache 11 Willktirbewegungen 16 Wisconsin Card Sorting Test 76

Z

Zungen- oder Augenmuskulatur 119 Zwangsbehandlung 98 zykloide Psychose 16, 24

Literatur

Agarwal MR. Subjective quality of life in schizophrenia. Br J Psychiatry 171 :392, 1997 Allebeck P, Varia A, Kristjansson E, et al: Risk factors for suicide among patients with

schizophrenia. Acta Psychiatr Scand 76:414-419, 1987 Amador XF, Sackheim HA, Mukerjee S, et al: Specificity of smooth pursuit eye movement

and visual fixation abnormalities in schizophrenia: comparison to mania and normal controls. Schizophrenia Research 5: 135-144, 1991

American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th Edition. Washington, DC, American Psychiatric Association, 1994

Andia AM, Zisook S, Heaton RK, et al. Gender differences in schizophrenia. Journal of Nervous and Mental Disease 183:522-528, 1995

Andreasen NC, Akiskal HS: The specificity of Bleulerian and Schneiderian symptoms: a critical reevaluation. Psychiatr C1in North Am 6:41-54, 1983

Andreasen NC, Arndt S, A1liger R, Miller D, Flaum M. Symptoms of schizophrenia: Methods, meanings, and mechanisms. Archives of General Psychiatty 52:341-351, 1995

Andreasen NC, Black DW: Schizophrenia, in Introductory Textbook of Psychiatry. Wa­shington, DC, American Psychiatric Press, 1991, pp 157-174

Andreasen NC, Carpenter WT Jr: Diagnosis and classification of schizophrenia. Schizophr Bull 19:199-214, 1993

Andreasen NC, Ehrhardt Jc, Swayze VW, et al: Magnetic resonance imaging of the brain in schizophrenia: the pathophysiologic significance of structural abnormalities. Arch gen Psychiar. 47:35-44, 1990

Andreasen NC, Flaum M, Swayze V, et al: Intelligence and brain structure in normal individuals. Am J Psychiatry 150: 130-134, 1993

Andreasen NC, Flaum M, Swayze VW, et al: Positive and negative symptoms in schizophrenia: a critical reappraisal. Arch Gen Psychiatry 47:615-621, 1990

Andreasen NC, Nasrallah HA, Dunn V, et al: Structural abnormalities in the ftontal system in schizophrenia: a magnetic resonance imaging study. Arch Gen Psychiatry 43:136-144,1986

Andreasen NC, Rezai K, A11iger R, et al: Hypofrontality in neuroleptic-naive patients and in patients with chronic schizophrenia: assessment with xenon 133 single-photon emission compured tomography and the Tower of London. Arch Gen Psychiauy 49:943-958,

139

Literatur

Andreasen NC, Smith MR, Jacoby CG, et al: Ventricular enlargement in schizophrenia: definition and prevalence. Am J Psychiatry 139:292-296, 1982

Andreasen NC, Swayze VW, Flaum M, et al: Ventricular enlargement in schizophrenia: evaluation with computed tomographic scanning. Arch Gen Psychiatry 47:1008-1015,1990

Andreasen NC: The diagnosis of schizophrenia. Schizophr Bull 13:9-22, 1987 Andreasen NS, Olsen S: Negative vs positive schizophrenia: definition and validation.

Arch Gen Psychiatry 39:789-794,1982 Angermeyer ML, Goldstein JM, Kuehn L: Gender differences in schizophrenia:

rehospitalization and community survival. Psychol Med 19:365-382, 1989 Arbeitsgemeinschaft fur Methodik und Dokumentation in der Psychiatrie. Das AMOP­

System, Manual zur Dokumentation psychiatrischer Befunde. Hogrefe: Gottingen, Bern, Toronto, Seattle 1995

Ariel RN, Golden CJ, Berg RA, et al: Regional cerebral blood flow in schizophrenics: tests using the xenon Xe 133 inhalation method. Arch Gen Psychiatry 40:258-263, 1983

Arnold SE, Hyman BT, Van Hoesen GW, et al: Some cyroarchitectural abnormalities of the entorhinal cortex in schizophrenia. Arch Gen Psychiatry 48:625-632, 1991

Arnold SE, Ruscheinsky DO, Han LY. Further evidence of abnormal cytoarchitecture of the entorhinal cortex in schizophrenia using spatial point pattern analyses. Bioi Psychiatry 42:639-647, 1997

Arvanitis LA, Miller BG, Borison RL, et al. Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: A comparison with haloperidol and placebo. Bioi Psychiatry 42:233-246, 1997

Astrup C: Querulent paranoia: a follow-up. Neuropsychobiology 11: 149-154, 1984 Aylward E, Walker E, Berres B: Intelligence in schizophrenia: meta-analysis of the research.

Schizophr Bull 10:430-459, 1984 Baldessarini RJ, Cohen BM, Teicher MH: Significance of neuroleptic dose and plasma

level in the pharmacologic treatment of psychoses. Arch Gen Psychiatry 45:79-91, 1988

Baldessarini RJ, Frankenburg FR: Clozapine - a novel antipsychotic agent. N Engl J Med 324:746-754,1991

Barr CE, Mednick SA, Munk-Jorgensen P: Exposure to influenza epidemics during gestation and adult schizophrenia: a 40-year srudy. Arch Gen Psychiatry 47:869-874, 1990

Barraclough B, Bunch J, Nelson B, et al: A hundred cases of suicide: clinical aspects. Br J Psychiatry 125:355-373, 1974

Barta PE, Pearlson GO, Powers RE, et al: Auditory hallucinations and smaller superior temporal gyral volume in schizophrenia. Am J Psychiatry 147: 1457-1462, 1990

Bebbington PE, Kuipers L: The social management of schizophrenia. Br J Hosp Med 28:396-403, 1982

Benes FM, McSparren J, Bird ED, et al: Deficits in small interneurons in prefrontal and cingulate cortices of schizophrenic and schizoaffective patients. Arch Gen Psychiatry 48:996-1001,1991

140

Literatur

Benes FM: An analysis of the arrangement of neurons in the cingulate cortex of schizophrenic patients. Arch Gen Psychiatry 44:608-616,1987

Berman KF, Torrey EF, Daniel DG, et al: Regional cerebral blood flow in monozygotic twins discordant and concordant for schizophrenia. Arch Gen Psychiatry 49:927-934, 1992

Bertelsen A, Gottesman II. Schizoaffective psychoses: Genetical clues to classification. American Journal of Medical Genetics 60:7-11, 1995

Black DW, Boffeli TJ: Simple schizophrenia: past, present, and future. Am J Psychiatry 146:1267-1273,1989

Black DW, Fisher R: Mortality in DSM-III-R schizophrenia. Schizophrenia Research 7: 1 09-116, 1992

Blackwood DHR, St Clair DM, Muir WJ, et al: Auditory P300 and eye tracking dysfunction in schizophrenic pedigrees. Arch Gen Psychiatry 48:899-909, 1991

Bleuler E: Dementia Praecox oder die Gruppe der Schizophrenien (I911) . Bogerts B, Ashtari M, Degreef G, et al: Reduced temporal limbic structure volumes on

magnetic resonance images in first episode schizophrenia. Psychiatry Research: Neuroimaging 35:1-13,1990

Bogerts B: Evidence for structural changes in the limbic system in schizophrenia, in Bio­logical Psychiatry. Edited by Shagass C. Amsterdam, Elsevier, 1986, pp 1178-1180

Bogerts B: Zur Neuropathologie der Schizophrenien. Fortschr Neurol Psychiatr 52:428-437,1984

Boyer P, Lecrubier Y, Puech AJ, Dewailly J, Aubin F. Treatment of negative symptoms in schizophrenia with amisulpride. British Journal of Psychiatry 166:68-72, 1995

Braff DL, Geyer MA: Sensorimotor gating and schizophrenia: human and animal model studies. Arch Gen Psychiatry 47: 181-188, 1990

Braff 0 L, Heaton R, Kuck J, et al: The generalized pa[(ern of neuropsychological deficits in outpatients with chronic schizophrenia with heterogeneous Wisconsin Card Sorting Test results. Arch Gen Psychiatry 48:891-898, 1991

Braff DL, Swerdlow NR. Neuroanatomy of schizophrenia. Schizophr Bull 23:509-512, 1997

Breier A, Astrachan BM: Characterization of schizophrenic patients who commit suicide. Am] Psychiatry 14 J :206-209, 1984

Brown Gw, Monck EM, Carstairs GM, et al: Influence of family life on the course of schizophrenic illness. British Journal of Preventative and Social Medicine 16:55-68, 1962

Brown R, Colter N, Corsellis JAN, et al : Postmortem evidence of strucrural brain changes in schizophrenia: differences in brain weight, temporal horn area and parahippocampal gyrus compared with affective disorders. Arch Gen Psychiatry 43:36-42, 1986

Buchanan RW, Carpenter WT,Jr .. The neuroanatomies of schizophrenia. Schizophr Bull 23:367-372, 1997

Buchanan RW, Stevens JR, Carpenter WT,Jr .. The neuroanatomy of schizophrenia: Introduction. Schizophr Bull 23:365-366, 1997

141

Literatur

Buchsbaum MS, DeLisi LE, Holcomb HH, et al: Antero-posterior gradients in cerebral glucose use in schizophrenia and affective disorders. Arch Gen Psychiatry 41: 1159-1166,1984

Buchsbaum MS, Haier R], Potkin SG, et al: Frontostriatal disorder of cerebral metabolism in never-medicated schizophrenics. Arch Gen Psychiatry 49:935-942, 1992

Cannon TO, Mednick SA, Parnas ], Schulsinger F, Praesthold ], Vestergaard A. Developmental brain abnormalities in schizophrenia: Contributions of genetic and perinatal factors. Reply. Archives of General Psychiatry 52: 157 -159, 1995

Cannon TO, Mednick SA, Parnas J: Genetic and perinatal determinants of structural brain deficits in schizophrenia. Arch Gen Psychiatry 46:883-889, 1989

Caracci G, Mukherjee S, Roth SO, et al: Subjective awareness of abnormal involuntary movements in chronic schizophrenic patients. Am J Psychiatry 147:295-298, 1990

Carlsson A: The current status of the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 1: 179-186, 1988

Carpenter WT Jr, Hanlon TE, Heinrichs Ow, et al: Continuous versus targeted medication in schizophrenic outpatients: outcome results. Am ] Psychiatry 147:1138-1148,1990

Carpenter WT J r, Strauss ]S: The prediction of outcome in schizophrenia, IV: eleven-year follow-up of the Washington IPSS cohort. J Nerv Ment Dis 179:5 17-525, 1991

Carpenter WT,jr., Conley RR, Buchanan RW, Breier A, Tamminga CA. Patient response and resource management: Another view of clozapine treatment of schizophrenia. American Journal of Psychiatry 152:827-832, 1995

Cheung P, Schweitzer I, Crowley K, Tuckwell V. Aggressive behaviour in schizophrenia: role of state versus trait factors. Psychiatry Res 72:41-50, 1997

Cheung P, Schweitzer I, Crowley K, Tuckwell V. Violence in schizophrenia: Role of hallucinations and delusions. Schizophr Res 26: 181-190, 1997

Collegium Internationale Psychiatriae Scalarum. Internationale Skalen fur Psychiatrie. Beltz-Test: Gottingen 1996

Conley RR, Buchanan RW. Evaluation of treatment-resistant schizophrenia. Schizophr Bull 23:663-674, 1997

Contad A], Scheibel AB: Schizophrenia and the hippocampus: the embryological hypothesis extended. Schizophr Bull 13:577-587, 1987

Corrigan PW, Gleason W, Cohler Bj, Luchins 0, Addis 1. Are there patients with late­onset schizophrenia in state hospitals? Schizophrenia Research 15:261-264, 1995

Coryell WH, Tsuang MT: Outcome after 40 years in DSM-III schizophreniform disorder. Arch Gen Psychiatry 43:324-328, 1986

Cramer P, Bowen ], O'Neill M: Schizophrenics and social judgement: why do schizophrenics get it wrong? Br j Psychiatry 160:481-487, 1992

Creese R, Burt BR, Snyder SH: Dopamine receptor binding predicts clinical and pharmacologic potencies of antipsychotic drugs. Science 192:81-84, 1976

Crow TJ, MacMillan JF, Johnson AL, et al: The Norrhwick Park Srudy of First Episodes of Schizophrenia, II: a randomised controlled study of prophylactic neuroleptic treatment. Br J Psychiatry 148: 120-127, 1986

142

Lirerarur

Crow TJ: Positive and negative schizophrenic symptoms and the role of dopamine. Br J Psychiatry 137:383-386, 1980

Cuesta MJ, Peralta V. Cognitive disorders in the positive, negative, and disorganization syndromes of schizophrenia. Psychiatry Research 58:227-235, 1995

Cutting]: Outcome of schizophrenia: overview, in Contemporary Issues in Schizophrenia. Edited by Kerr TA, Snaith P. Washington, DC, American Psychiatric Press, 1986, pp 433-440

Czobor P, Volavka J, Meibach RC. Effect of risperidone on hostility in schizophrenia. J Clin Psychopharmacol:243-249, 1995

Davila R, Zumarraga M, Gonzalez-Torres MA, et al. Schizophrenia: Gender, family risk, and plasma homovanillic acid. American Journal of Medical Genetics 60: 154-156, 1995

Davis JM: Overview: maintenance therapy in psychiatry, I: schizophrenia. Am J Psychiatry 132:1237-1245,1975

Davis KL, Kahn RS, Ko G, et al: Dopamine in schizophrenia: a review and reconceptualization. Am J Psychiatry 148: 1474-1486, 1991

Davison K, Bagley CR: Schizophrenia-like psychoses associated with organic disorders of the CNS: a review of the literature, in Current Problems in Neuropsychiatry, Parr II (British Journal of Psychiatry, Special Publication No 4). Edited by Herrington E. Ashford, Headley Bros, 1969, pp 113-184

Davison K: Schizophrenia-like psychoses associated with organic cerebral disorders: a review. Psychiatr Dev 1:1-34,1983

De Leon J, Dadvand M, Canuso C, White AO, Stan ilia JK, Simpson GM. Schizophrenia and smoking: An epidemiological survey in a state hospital. American Journal of Psychiatry 152:453-455, 1995

Delini-Stula A, Berdah-Tordjman D. Benzodiazepines and GABA hypothesis of schizophrenia. Journal of Psychopharmacology 9:57-63, 1995

DeLisi LE, Goldin LR, Hamovit JR, et al: A family study of the association of increased ventricular size with schizophrenia. Arch Gen Psychiatry 43: 148-153, 1986

DeLisi LE. Gender and age at onset of schizophrenia. Br J Psychiatry 171: 188, 1997 DeMyer MK, Gilmor RL, Hendrie HC, et al: Magnetic resonance brain images in

schizophrenic and normal subjects: influence of diagnosis and education. Schizophr Bull 14:21-37, 1988

DeVane CL. Brief comparison of the pharmacokinetics and pharmacodynamics of the traditional and newer antipsychotic drugs. American Journal of Hospital Pharmacy 52, Suppl. 1: 15-S 18, 1995

DeVito RA, Brink L, Sloan C, et al: Fluphenazine decanoate vs oral antipsychotics: a comparison of their effectiveness in the treatment of schizophrenia as measured by a reduction in hospital readmissions. J Clin Psychiatry 39:26-34, 1978

Dickson RA, Dalby JT, Williams R, Edwards AL. Risperidone-induced prolactin elevations in premenopausal women with schizophrenia. American Journal of Psychiatry 152: 1102-1103, 1995

Dierks T, Strik WK, Maurer K. Electrical brain activity in schizophrenia described by equivalent dipoles ofFFT-data. Schizophrenia Research 14:145-154, 1995

143

Literatur

Dilling H, Mombour W, Schmidt M H, Schulte-Markwort E. Internationale Klassifika­tion psychischer Storungen, ICD-10, Kapitel V (F), Forschungskriterien. I. Auf!. Huber: Bern, Gottingen, Toronto, Seattle 1994

Dixon L, Haas G, Weiden PJ, et al: Drug abuse in schizophrenic patients: clinical correlates and reasons for use. Am J Psychiatry 148:224-230, 1991

Dollfus S, Brazo P. Clinical heterogeneity of schizophrenia. Psychopathology 30:275-281, 1997 Dollfus S, Petit M. Principal-component analyses of PANSS and SANS-SAPS in

schizophrenia: Their stability in an acute phase. European Psychiatry 10:97-106, 1995

Drake RE, Osher FC, Wallach MA: Alcohol use and abuse in schizophrenia: a prospective community study. J Nerv Ment Dis 177:408-414, 1989

Dworkin RH, Cornblatt BA. Predicting schizophrenia. Lancet 345: 139-140, 1995 Dysken MW, Merry W, Davis JM: Anticholinergic psychosis. Psychiatric Annals 8:30-35,

1978 Eaton WW, Thara R, Federman B, Melton B, Liang K. Structure and course of positive

and negative symptoms in schizophrenia. Archives of General Psychiatry 52: 127 -134, 1995

Eaton WW: Epidemiology of schizophrenia. Epidemiol Rev 7: 105-126, 1985 Eaton WW: Update on epidemiology of schizophrenia. Epidemiol Rev 13:320-328, 1991 Ebmeier KP, Lawrie SM, Blackwood DHR, Johnstone EC, Goodwin GM. Hypofrontality

revisited: A high resolution single photon emission computed tomography study in schizophrenia. Journal of Neurology,Neurosurgcry and Psychiatry 58:452-456, 1995

Ellsworth RB: Characteristics of effective treatment milieu, in Principles and Practice of Milieu Therapy. Edited by Gunderson JG, Will OA, Mosher LF. New York, Jason Aronson, 1983, pp 87-123

Elomaa E. Schizophrenia: A scientific delusion with long-lasting computer virus-like action on human thought. Medical Hypotheses 44: 110, 1995

hlkai P, Bogerts B, Schneider T, et al. Disturbed planum temporale asymmetry in schizophrenia. A quantitative post-mortem study. Schizophrenia Research 14: 161-176, 1995

Falloon IRH, Boyd JL, McGill CW, et al: Family management in the prevention of morbidity of schizophrenia: clinical outcome of a two-year longitudinal study. Arch Gen Psychiatry 42:887-896, 1985

Falloon IRH, Boyd JL, McGill CW: Family Care of Schizophrenia: A Problem-Solving Approach to the Treatment of Mental Illness. New York, Guilford, 1984

Farde L, Nordstrom A-L, Karlsson 1~ Halldin C, Sedvall G. Positron emission tomography studies on dopamine receptors in schizophrenia. Clinical Neuropharmacology 18:S121-S129,1995

Farde L, Wiesel F-A, Stone-Elander S, et al: 02 dopamine receptors in neuroleptic-naive schizophrenic patients: positron emission tomography study with [11Clraclopride. Arch Gen Psychiatry 47:213-219, 1990

Farmer A, Jackson R, McGuffin P, et al: Cerebral ventricular enlargement in chronic schizophrenia: consistencies and contradictions. Br J Psychiatry 150:324-330, 1987

144

Literatur

Farmer AE, McGuffin P, Gottesman II: Twin concordance for DSM-III schizophrenia: scrutinizing the validity of the definition. Arch Gen Psychiatry 44:634-641, 1987

Feighner ]P, Robins E, Guze SB, et al: Diagnostic criteria for use in psychiatric research. Arch Gen Psychiatry 26:57-63, 1972

Fenton WS, McGlashan TH. We can talk: Individual psychotherapy for schizophrenia. Am] Psychiatry 154:1493-1495,1997

Fenton WS, McGlashan TH: Natural hisrory of schizophrenia subtypes, I: longitudinal study of paranoid, hebephrenic, and undifferentiated schizophrenia. Arch Gen Psychiatry 48:969-977,1991

Fitzgerald LW, Deutch AY, Gasic G, Heinemann SF, Nestler E]. Regulation of cortical and subcortical glutamate recepror subunit expression by antipsychotic drugs. Journal of Neuroscience 15:2453-2461, 1995

Flaum M, Arndt S, Andreasen NC: The role of gender in studies of ventrical enlargement in schizophrenia: a predominantly male effect. Am J Psychiatry 147:1327-1332, 1990

Flor-Henry P: Psychosis and temporal lobe epilepsy: a controlled investigation. Epilepsia 10:363-395, 1969

Frank AF, Gunderson JG: The role of the therapeutic alliance in the treatment of schizophrenia: relationship ro course and outcome. Arch Gen Psychiatry 47:228-236, 1990

Franz M. Subjective quality oflife in schizophrenia - Reply. Br J Psychiatry 171 :392, 1997 Friedman L, Knutson L, Shurell M, et al: Prefrontal sulcal prominence is inversely related

to response ro c10zapine in schizophrenia. Bioi Psychiatry 29:865-877, 1991 Frith CD. Functional brain imaging and the neuropathology of schizophrenia. Schizophr

Bull 23:525-527, 1997 Fromm-Reichmann F: Notes on the development of treatment of schizophrenics by

psychoanalytic psychotherapy. Psychiatry 11 :263-273, 1948 Geaney D . Clozapine can cause hallucinations by inducing complex partial seizures of

temporal lobe origin (temporal lobe epilepsy). A potentially serious complication in the management of schizophrenia with c1ozapine. Journal of Psychopharmacology 9:64-66. 1995

George MS, Scon T, Kellner CH, et al: Abnormalities of the septum pellucidum in schizophrenia. Journal of Neuropsychiatry and Clinical Neurosciences 1:385-390, 1989

Gerez M, Tello A. Selected quantitative EEG (QEEG) and event-related potential (ERP) variables as discriminators for positive and negative schizophrenia. Biological Psychiatry 38:34-49, 1995

Goldberg TE, Gold JM, Torrey EF, Weinberger DR. Lack of sex differences in the neuropsychological performance of patients with schizophrenia. American Journal of Psychiatry 152:883-888, 1995

Goodwin D, Guze SB: Psychiatric Diagnosis, 3rd Edition. New York, Oxford University Press, 1984

Grebb JA, Weinberger DR, Morihisa JM: Electroencephalograph and evoked potential

145

Literatur

studies of schizophrenia, in Handbook of Schizophrenia, Vol I: The Neurology of Schizophrenia. Edited by Weinberger DR, Nasrallah HA. New York, Elsevier, 1986

Grech A, Takei N, Murray RM. Maternal exposure to influenza and paranoid schizophrenia. Schizophr Res 26:121-125,1997

Greden JF, Tandon R (eds): Negative Schizophrenic Symptoms: Pathophysiology and Clinical Implications. Washington, DC, American Psychiatric Press, 1991 Goff DC, Henderson DC, Amico E: Cigarette smoking in schizophrenia: relationship to psychopathology and medication side effects. Am J Psychiatry 149: 1189-1194, 1992

Grove WM: Psychometric detection of schizotypy. Psychol Bull 92:27-.')8, 1982 Gunderson JG, Mosher LR: The cost of schizophrenia. Am J Psychiatry 132:901-906,

1975 Gupta SK, Kunka RL, Metz A, Lloyd T, Rudolph G, Perel JM . Effect of alosetron (a new 5-

HT-3 receptor antagonist) on the pharmacokinetics of haloperidol in schizophrenic patients. J Clin Pharmacol:202-207, 1995

Cur RE, Mozley PO, Resnick SM, et al. Resting cerebral glucose metabolism in first­episode and previously treated patients with schizophrenia relates to clinical features. Archives of General Psychiatry 52:657-667,1995

Gurevich EV, Joyce IN. Alterations in the cortical serotonergic system in schizophrenia: A postmortem study. BioI Psychiatry 42:529-545, 1997

Cuze SB, Cloninger CR, Martin RL, et al: A follow-up and family study of schizophrenia. Arch Gen Psychiatry 40:1273-1276, 1983

Hafner H, K1ug J: First evaluation of the Mannheim Community Mental Health Service. Acta Psychiatr Scand Suppl 285:68-78, 1980

Hafner H. Epidemiology of schizophrenia. The disease model of schizophrenia in the light of current epidemiological knowledge. Eur Psychiatry 10:217-227, 1995

Hahlweg K. The role of interpersonal factors on course and treatment of mental and somatic disorders. Verhaltenstherapie 5: 1-8, 1995

Hamera E, Schneider JK, Deviney S. Alcohol, cannabis, nicotine, and caffeine use and symptom distress in schizophrenia. Journal of Nervous and Mental Disease 183:559-565, 1995

Hare EH, Price JS, Slater E: Mental disorder and season of birth. Narure 24:480, 1973 Hare EH: Mental illness and social conditions in Bristol. Journal of Mental Science

102:349-357, 1956 Harvey PO, White L, Parrella M, et al. The longirudinal stability of cognitive impairment

in schizophrenia. Mini-mental state scores at one- and two-year follow-ups in geriatric in-patients. British Journal of Psychiatry 166:630-633, 1995

Heaton R: Wisconsin Card Sorting Test. Odessa, TX, Psychological Assessment Resources, 1985

Heckers S. Neuropathology of schizophrenia: Cortex, thalamus, basal ganglia, and neurotransmitter-specific projection systems. Schizophr Bull 23:403-421, 1997

Heila H, Isometsa ET, Henriksson MM, Heikkinen ME, Marttunen MJ, Lonnqvist JK. Suicide and schizophrenia: A nationwide psychological autopsy study on age- and

146

Literatur

sex-specific clinical characteristics of 92 suicide victims with schizophrenia. Am J Psychiatry 154: 1235-1242. 1997

Heinrichs OW; Buchanan RW: Significance and meaning of neurological signs in schizophrenia. Am J Psychiatry 145: 11-18, 1988

Henn FA, Herjanic M, Vanderpearl RH: Forensic psychiatry: diagnosis and criminal responsibility. J Nerv Ment Dis 162:423-429, 1976

Henn FA, Nasrallah HA (eds): Schizophrenia as a Brain Disease. New York, Oxford University Press, 1982

Herrman HE, Baldwin JA, Christie 0: A record linkage study of mortality and general hospital discharge in patients diagnosed as schizophrenic. Psychol Med 13:581-593, 1983

Herz M: Prodromal symproms and prevention of relapse in schizophrenia. J Clin Psychiatry 46 (No 11, Sec 2):22-25, 1985

Heston LL: Psychiatric disorders in foster home reared children of schizophrenic mothers. Br J Psychiatry 112:819-825, 1966

Hogarty GE, Kornblith SJ, Greenwald 0, et at. Personal therapy: A disorder-relevant psychotherapy for schizophrenia. Schizophr Bull 21 :379-393, 1995

Hogarty GE, McEvoy JP, Ulrich RF, et at. Pharmacotherapy of impaired affect in recovering schizophrenic patients. Arch Gen Psychiatry:29-41, 1995

Hogarty GE: Depot neuroleptics: the relevance of psychosocial factors-a United States perspective. J Clin Psychiatry 45 (No 5, Sec 2):36-42, 1984

Hokfelt T, LindbergJM, Schultzberg M: Coexistence of peptides and purative transmitters in neurons, in Neuropeptides and Neuronal Communication. Edited by Costa E, Trabuchi A. New York, Raven, 1980, pp 1-23

Holden RJ. Schizophrenia, suicide and the serotonin story. Med Hypotheses 44:379-391, 1995

Hollingshead AB, Redlich FC: Social Class and Mental Illness: A Community Study. New York, Wiley, 1958

Holzman PS, Kringlen E, Matthysse S, et al: A single dominant gene can account for eye tracking dysfunctions and schizophrenia in offspring of discordant twins. Arch Gen Psychiatry 45:641-647,1988

Holzman PS, Solomon CM, Levin S, et al: Pursuit eye movement dysfunctions in schizophrenia: family evidence for specificity. Arch Gen Psychiatry 41: 136-139, 1984

Hwu H-G, Tan H, Chen C-C, Yeh L-L. Negative symptoms at discharge and outcome in schizophrenia. British Journal of Psychiatry 166:61-67, 1995

Ingvar DH, Franzen G: Abnormalities of cerebral blood flow distribution in patients with chronic schizophrenia. Acta Psychiatr Scand 50:425-462, 1974

Ingvar DH: Evidence for frontal/pre-frontal cortical dysfunction in chronic schizo­phrenia: the phenomenon of hypofrontality reconsidered, in Biological Perspec­tives of Schizophrenia. Edited by Helmchen H, Henn FA. New York, John Wiley, 1987

Jaber M, Jones S, Giros B, Caron MG. The dopamine transporter: A crucial component regulating dopamine transmission. Mov Disord 12:629-633, 1997

147

Literatur

Jablensky A, Sartorius N: Culture and schizophrenia. Psychol Med 5: 113-124, 1975 Jablensky A. Schizophrenia: Recent epidemiologic issues. Epidemiol Rev 17: 1 0-20, 1995 Jakob J, Beckmann H: Prenatal developmental disturbance in the limbic allocortex in

schizophrenics. J Neural Transm 65:303-326, 1986 Janowsky MS, EI-YousefMK, Davis JM, et al: Provocation of schizophrenic symptoms by

intravenous administration of methylphenidate. Arch Gen Psychiatry 28: 185-191, 1973

Javitt DC, Zukin SR: Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 148:1301-1308,1991

Jernigan TL, Zisook S, Heaton RK, et al: Magnetic resonance imaging abnormalities in lenticular nuclei and cerebral cortex in schizophrenia. Arch Gen Psychiatry 48:881-890,1991

Johnson AL, Johnson DAW. Peer review of"Risperidone in the treatment of patients with chronic schizophrenia: A multi-national, multi-centre, double-blind, parallel-group study versus haloperidol". British Journal of Psychiatry 166:727-731. 1995

Johnstone EC, Crow TJ, Frith CD, et al: Cerebral ventricular size and cognitive impairment in chronic schizophrenia. Lancet 2:924-926, 1976

Johnstone EC, Owens DGC, Bydder GM, et al: The spectrum of structural brain changes in schizophrenia: age of onset as a predictor of cognitive and clinical impairments and their cerebral correlates. Psychol Med 19:91-103, 1989

Jonsson H, Nyman AK: Prediction of outcome in schizophrenia. Acta Psychiatr Scand 69:274-291, 1984

Kajimura N, Kato M, Okuma T, 5ekimoto M, Watanabe T, Takahashi K. A quantitative sleep-EEG study on the effects of benzodiazepine and zopiclone in schizophrenic patients. Schizophrenia Research 15:303-312, 1995

Kalus P, Senitz D, Beckmann H. Altered distribution of parvalbumin-immunoreactive local circuit neurons in the anterior cingulate cortex of schizophrenic patients. Psychiatry Res Neuroimaging 75:49-59, 1997

Kalus P, Senitz D, Beckmann H. Cortical layer I changes in schizophrenia: A marker for impaired brain development? J Neural Transm 104:549-559, 1997

Kanas N: Inpatient and outpatient group therapy for schizophrenic patients. Am J Psychother 39:431-439,1985

Kane JM, Rifkin A, Woerner M, et al: Low-dose neuroleptic treatment of outpatient schizophrenics, I: preliminary results for relapse rates. Arch Gen Psychiatry 40:893-896, 1983

Kane JM. Current problems with the pharmacotherapy of schizophrenia. Clinical Neuropharmacology 18:5154-5161, 1995

Kane JM: Antipsychotic drug side effects: their relationship to dose. J Clin Psychiatry 46 (No 5, Sec 2):16-21, 1985

Kane J[M], Honigfeld G, Singer ], et al: Clozapine for the treatment-resistant schizophrenic: a double-blind comparision with chlorpromazine. Arch Gen Psychiatry 45:789-796, 1988

Kapur S, Remington G, Zipursky RB, Wilson AA, Houle S. The D2 dopamine receptor

148

Literatur

occupancy of risperidone and its relationship to extrapyramidal symptoms: A pet study. Life Sciences 57:PLl03-PLl07, 1995

Keefe RS, Lees-Roitman SE, Dupre RL. Performance of patients with schizophrenia on a pen and paper visuospatial working memory task with short delay. Schizophr Res 26:9-14, 1997

Keilp JG , Sweeney JA, Jacobsen P, et al: Cognitive impairment in schizophrenia: specific relations to ventricular size and negative symptomatology. Bioi Psychiatry 24:47-55, 1988

Keith SJ. Pharmacologic advances in the treatment of schizophrenia. N Engl J Med 337:851-852,1997

Keks NA, Copolov DL, McKenzie DP, et al. Basal and haloperidol-stimulated prolactin and symptoms of non affective and affective psychoses in neuroleptic-free men. Biological Psychiatry 37:229-234, 1995

Kemali D, Maj M, Galderisi S, et al: Ventricle-to-brain ratio in schizophrenia: a controlled follow-up study. Bioi Psychiatry 26:756-759,1989

Kendell RE, Kemp IW: Maternal influenza in the etiology of schizophrenia. Arch Gen Psychiatry 46:878-882, 1989

Kendler KS, Gruenberg AM, Strauss JS: An independent analysis of the Copenhagen sample of the Danish Adoption Study of Schizophrenia, III: the relationship between paranoid psychosis (delusional disorder) and the schizophrenia spectrum disorders. Arch Gen Psychiatry 38:985-987,1981

Kendler KS , Gruenberg AM, Tsuang MT: A family study of the subtypes of schizophrenia. Am] Psychiatry 145:57-62,1988

Kendler KS, Gruenberg AM, Tsuang MT: Outcome of schizophrenic subtypes defined by four diagnostic systems. Arch Gen Psychiatry 41: 149-154, 1984

Kendler KS, Gruenberg AM: An independent analysis of the Danish Adoption Study of Schizophrenia, VI: the relationship between psychiatric disorders as defined by DSM­III in the relatives and adoptees. Arch Gen Psychiatry 41 :555-564, 1984

Kendler KS, Masterson CC, Davis KL: Psychiatric illness in first-degree relatives of patients with paranoid psychosis, schizophrenia and medical illness. Br J Psychiatry 147:524-531,1985

Kendler KS , Tsuang MT, Hays P: Age at onset in schizophrenia: a familial perspective. Arch Gen Psychiatry 44:881-890, 1987

Kendler KS: Demography of paranoid psychosis (delusional disorder): a review and comparison with schizophrenia and affective illness. Arch Gen Psychiatry 39:890-902, 1982

Kennedy HG, Kemp U , Dyer DE: Fear and anger in delusional (paranoid) disorder: the association with violence. Br J Psychiatry 160:488-492, 1992

Kentros M, Smith TE, Hull J, McKee M, Terkelsen K, Capalbo C. Stability of personality traits in schizophrenia and schizoaffective disorder: A pilot project. J Nerv Ment Dis 185:549-555, 1997

Kerwin RW. Clozapine: Back to the future for schizophrenia research. Lancet 345: 1063-1064, 1995

149

Literatur

Kety 55, Rosenthal D, Wender PH, et al: Mental illness in the biologic and adoptive families of adopted individuals who have became scbizophrenic: a preliminary report based on psychiatric interviews, in Genetic Research in Psychiatry. Edited by Fieve R, Rosenthal D, Brill H. Baltimore, MD, Johns Hopkins Press, 1975, pp 147-165

King 5, Dixon MJ. Expressed emotion, family dynamics and symptom severity in a predictive model of social adjustment for schizophrenic young adults. Schizophrenia Research 14:121-132,1995

Kirkpatrick B, Carpenter WT Jr. Drug development and the deficit syndrome of schizophrenia. Biological Psychiatry 38:277-278, 1995

Kissling W (ed): Guidelines for Neuroleptic Relapse Prevention in Schizophrenia. Berlin, Springer-Verlag, 1991

Klawans HL: Levodopa-induced psychosis. Psychiatric Annals 8: 19-22, 1978 Klieser E, Lehmann E, Kinzler E, Wurthmann C, Heintich K. Randomized, double-blind,

controlled trial of risperidone versus clozapine in patients with chronic schizophrenia. Journal of Clinical Psychopharmacology 15 Supp!. 1:45S-51S, 1995

Kraepelin E: Dementia Praecox and Paraphrenia. 1919 Krakowski MI, Convit A, Jaeger J, et al: Neurological impairment in violent schizophrenic

inpatients. Am J Psychiatry 146:849-853, 1989 Krimer LS, Herman MM, Saunders RC, et a!. A qualitative and quantitative analysis of the

entorhinal cortex in schizophrenia. Cereb Cortex 7:732-739,1997 Kubagawa T, Furusho J, Maruyama H. Study of psychiatric symptoms after

discontinuation of antiepileptic drugs. Epilepsia 38:26-31, 1997 Kulynych Jj, Vladar K, Fantie BD, Jones DW, Weinberger DR. Normal asymmetry of the

planum temporale in patients with schizophrenia. Three-dimensional cortical morphometry with MRI. British Journal of Psychiatry 166:742-749, 1995

Kunugi H, Nanko S, Takei N, Saito K, Hayashi N, Kazamatsuri H. Schizophrenia following in utero exposure to the 1957 influenza epidemics in Japan. American Jour­nal of Psychiatry 152:450-452, 1995

Lahti AC, Tamminga CA. Recent developments in the neuropharmacology of schizophrenia. American Journal of Hospital Pharmacy 52 Supp!. 1:55-58, 1995

Lang FH, Forbes JF, Murray GD, Johnstone Ee. Service provision for people with schizophrenia. I. Clinical and economic perspective. Br J Psychiatry 171: 159-164, 1997

Lang FH, Johnstone EC, Murray GD. Service provision for people with schizophrenia. 2. Role of the general practitioner. Br J Psychiatry 171: 165-168, 1997

Lawrie SM, Ingle GT, Santosh CG, et a!. Magnetic resonance imaging and single photon emission tomography in treatment-responsive and treatment-resistant schizophrenia. British Journal of Psychiatry 167:202-210, 1995

Leff J, Berkowitz R, Shavit N, et al: A trial of family therapy versus a relatives' group for schizophrenia: two-year follow-up. Br J Psychiatry 157:571-577,1990

Leff J: Social and psychological causes of the acute attack, in Schizophrenia: Towards a New Synthesis. Edited by Wing JK. London, Academic, 1978, pp 139-165

Lehmann HE, Wilson H, Deutsch M: Minimal maintenance medication: effect of three

150

Lirerarur

dose schedules on relapse rates and symptoms in chronic schizophrenic outpatients. Compr Psychiatry 24:293-303, 1983

Leonhard K, Die Aufteilung der endogenen Psychosen und ihre differenzierte Atiologie. Thieme-Verlag. 7. Auflage 1994

Levkovitch Y, Kronenberg], Kayser N, Zvyagelski M, Gaoni B, Gadoth N. Clozapine for tardive dyskinesia in adolescents. Brain Dev 17:213-215, 1995

Lewine R, Butbach D, Melzer HY: Effect of diagnostic criteria on the ratio of male to female schizophrenic patients. Am] Psychiatry 141:84-87, 1984

Lewine RRJ, Hudgins P, Brown F, Caudle ], Risch Sc. Differences in qualitative brain morphology findings in schizophrenia, major depression, bipolar disorder and nor­mal volunteers. Schizophrenia Research 15:253-259, 1995

Lewis SW, Murray RM: Obstetric complications, neurodevelopmental deviance and risk for schizophrenia. ] Psychiatr Res 21 :413-421, 1987

Liddle PF, CrowT]: Age disorientation in chronic schizophrenia is associated with global intellectual impairment. Br] Psychiatry 144: 193-199, 1984

Lieberman JA, Kane JM, Sarantakos S, et al: Prediction of relapse in schizophrenia. Arch Gen Psychiatry 44:597-603, 1987

Lieberman JA. Signs and symptoms: What can they tell us about the clinical course and pathophysiologic processes of schizophrenia. Archives of General Psychiatry 52:361-362,1995

Lindenmayer ]-P, Grochowski S, Hyman RB. Five factor model of schizophrenia: Replication across samples. Schizophrenia Research 14:229-234, 1995

Loranger AW: Sex difference in age at onset of schizophrenia. Arch Gen Psychiatry 41: 157-161, 1984

Losonczy MF, Song IS, Mohs RC, et al: Correlates of lateral ventricular size in chronic schizophrenia, I: behavioral and treatment response measutes. Am ] Psychiatry 143:976-981, 1986

Losonczy MF, Song IS, Mohs RC, et al: Correlates of lateral ventricular size in chronic schizophrenia, II: biological measures. Am] Psychiatry 143: 1113-1118, 1986

Lund TR, Sponheim SR, Iacono WG, Clementz BA. Internal consistency reliability of resting EEG power spectril in schizophrenic and normal subjects. Psychophysiology 32:66-71,1995

Lyon M, Barr CE, Cannon TD, et al: Fetal neural development and schizophrenia. Schizophr Bull 15: 149-161, 1989

Lysaker P, Bell M, Beam-Goulet]. Wisconsin Card Sorting Test and work performance in schizophrenia. Psychiatry Research 56:45-51, 1995

Mackert A, Flechrner KM, Woyth C, et al: Increased blink rates in schizophrenics: influences of neuroleptics and psychopathology. Schizophrenia Research 4:41-47, 1991

Maes M, Bosmans E, Kenis G, De long R, Smith RS, Meltzer HY. In vivo immunomodulatory effects of clozapine in schizophrenia. Schizophr Res 26:221-225, 1997

Magliano L, Veltro F, Guarneri M, Marasco C. Clinical and socio-demographic correlates

151

Literatur

of coping strategies in relatives of schizophrenic patients. Eur Psychiatry 10: 155-158, 1995

Magrinat G, Danziger JA, Lorenzo IC, et al: A reassessment of catatonia. Compr Psychiatry 24:218-228, 1983

Manschreck TC, Maher BA, Beaudette SM, Redmond DA. Context memory in schizoaffective and schizophrenic disorders. Schizophr Res 26: 153-161, 1997

Manschreck TC, Maher BA, Rucklos ME, et al: Disturbed voluntary motor activity in schizophrenic disorder. Psychol Med 12:73-84, 1982

Mathew RJ, Duncan GC, Weinman ML, et al: Regional cerebral blood flow in schizophrenia. Arch Gen Psychiatry 39: 1121-1124, 1982

Maurer K, Hafner H. Methodological aspects of onset assessment in schizophrenia. Schizophrenia Research 15:265-276, 1995

Mauri MC, Bravin S, Mantero M, Invernizzi G. Depression in schizophrenia: Clinical and pharmacological variables. Schizophrenia Research 14:261-262, 1995

May PRA, TumaAH, Dixon WJ: Schizophrenia - a follow-up study of results of treatment, I: design and other problems. Arch Gen Psychiatry 33:474-478, 1976

McCabe MS, Fowler RC, Cadoret RJ, et al: Symptom differences in schizophrenics with good and poor prognosis. Am J Psychiatry 128: 1239-1243, 1972

McCarley RW, Faux SF, Shenton M, et al: CT abnormalities in schizophrenia: a preliminary study of their correlation with P300/P200 electrophysiological features and positive/negative symptoms. Arch Gen Psychiatry 46:698-708, 1989

McEvoy J, Freudenreich 0, McGee M, VanderZwaag C, Levin E, Rose J. Clozapine decreases smoking in patients with chronic schizophrenia. Biological Psychiatry 37:550-552, 1995

McEvoy JP, Freudenreich 0, Levin ED, Rose JE. Haloperidol increases smoking in patients with schizophrenia. Psychopharmacology 119:124-126,1995

McEvoy JP, Hogarty GE, Steingard S: Optional dose of neuroleptic in acute schizophrenia: a controlled study of the neuroleptic threshold and higher haloperidol dose. Arch Gen Psychiatry 48:739-745,1991

McGlashan TH: The Chesrnur Lodge Follow-up Study, II: long-term outcome of schizophrenia and the affective disorders. Arch Gen Psychiatry 41 :586-60 1, 1984

McGlashan TH: The prediction of ourcome in chronic schizophrenia, IV: The Chestnut Lodge Follow-up Study. Arch Gen Psychiatry 43: 167 -176, 1986

McGrath J, Scheldt S, Welham J, Clair A. Performance on tests sensitive to impaired executive ability in schizophrenia, mania and well controls: acute and subacute phases. Schizophr Res 26:127-137,1997

McGuffin P, Owen M], Farmer AE. Genetic basis of schizophrenia. Lancet 346:678-682, 1995

McGuire PK, Jones P, Harvey I, Williams M, McGuffin P, Murray RM. Morbid risk of schizophrenia for relatives of patients with cannabis-associated psychosis. Schizophrenia Research 15:277-281, 1995

Mednick SA, Machon RA, Huttunen MO, et al: Adult schizophrenia following prenatal exposure to an influenza epidemic. Arch Gen Psychiatry 45: 189-192, 1988

152

Lirerarur

Mellon CD, Byerley WF: Strategies for linkage studies in schizophrenia. Schizophrenia Research 2:277-285,1989

Meltzer HY, Okayli G. Reduction of suicidaliry during c10zapine treatment of neuroleptic­resistant schizophrenia: Impact on risk-benefit assessment. American Journal of Psychiatry 152: 183-190, 1995

Meltzer HY. The role of serotonin in schizophrenia and the place of serotonin-dopamine antagonist antipsychotics. Journal of Clinical Psychopharmacology 15 Supp!. 1 :25-3S, 1995

Meltzer HY: Biological studies in schizophrenia. Schizophr Bull 13:77-111, 1987 Miller DD, Andreasen NC, O'Leary DS, et al. Effect of antipsychotics on regional cerebral

blood flow measured with Positron Emission Tomography. Neuropsychopharma­cology 17:230-240, 1997

Moberg PJ, Dory RL, Mahr RN, et al. Olfactory identification in elderly schizophrenia and Alzheimer's disease. Neurobiol Aging 18:163-167, 1997

Moller HJ, Boyer P, Fleurot 0, Rein W Improvement of acute exacerbations of schizophrenia with amisulpride: a comparison with haloperidol. Psycho­pharmacology (Berl) 132:396-401, 1997

Mooney HB: Pathologic jealousy and psychochemotherapy. Br J Psychiatry 111: 1 023-1042, 1965

Morihisa JM, DuffY FH, Wyatt RJ, et al: Brain electrical activiry mapping in schizophrenic patients. Arch Gen Psychiatry 40:719-728, 1983

Mueser KT, Berenbaum H: Psychodynamic treatment of schizophrenia: is there a future? Psychol Med 20:253-262, 1990

Mukherjee S, Shukla S, Woodle J, et al: Misdiagnosis of schizophrenia in bipolar patients: a multiethnic comparison. Am J Psychiatry 140: 1571-1574, 1983

Mundt C, Barnett W, Witt G. The core of negative symptoms in schizophrenia: Affect or cognitive deficiency. Psychopathology 28:46-54, 1995

Munk-Jorgensen P. Decreasing rates of incident schizophrenia cases in psychiatric service: A review of the literature. Eur Psychiatry 10: 129-141, 1995

Murphy HBM, Raman AC: The chronicity of schizophrenia in indigenous tropical peoples: results of a twelve-year follow-up survey in Mauritius. Br J Psychiatry 118:489-497,1971

Nasrallah HA, Kuperman S, Hamra B, et al: Schizophrenia patients with and without large cerebral ventricles: a controlled clinical comparison. J Clin Psychiatry 44: 407-409, 1983

Nasrallah HA, McCalley-Whitters M, Jacoby CG: Cortical atrophy in schizophrenia and mania: a comparative CT study. J Clin Psychiatry 43:439-441, 1982

Nasrallah HA, Olson SC, Coffman JA, et al: Magnetic resonance brain imaging, perinatal injury, and negative symptoms in schizophrenia. Schizophrenia Research I: 171-172, 1988

Nasrallah HA, Schwarzkopf SB, Olson SC, et al: Gender differences in schizophrenia on MRI scans. Schizophr Bull 16:205-210, 1990

Nasrallah HA: The differential diagnosis of schizophrenia: genetic, perinatal, neurological,

153

Literatur

pharmacological and psychiatric factors, in Handbook of Schizophrenia, Vol 1: The Neurology of Schizophrenia. Edited by Weinberger DR, Nasrallah HA. New York, Elsevier, 1986

Nibuya M, Kanba S, Sekiya U, et al. Schizophrenic patients with deficit syndrome have high):r plasma homovanillic acid concentrations and ventricular enlargement. Biological Psychiatry 38: 50-56, 1995

Noble P. Crime, violence and schizophrenia. Br J Psychiatry 171: 189-190, 1997 Nugter A, Dingemans P, Van der Does JW, Linszen D, Gersons B. Family treatment,

expressed emotion and relapse in recent onset schizophrenia. Psychiatry Res 72:23-31,1997

Owens DGC, Johnstone EC, Bydder GM, et al: Unsuspected organic disease in chronic schizophrenia demonstrated by computed tomography. J Neurol Neurosurg Psychiatry 43: 1065-1069, 1980

Pakkenberg B: Post-mortem study of chronic schizophrenic brains. Br J Psychiatry 151:744-752,1987

Pantel is C, Barnes TR, Nelson HE, et al. Frontal-striatal cognitive deficits in patients with chronic schizophrenia. Brain 120: 1823-1843, 1997

Parker G, Johnston P, Hayward L: Parental "expressed emotion" as a predictor of schizophrenic relapse. Arch Gen Psychiatry 45:806-813, 1988

Pearlson GD, Garbacz DJ, Moberg PJ, et al: Symptomatic, familial, perinatal, and social correlates of computerized axial tomography (CAT) changes in schizophrenics and bipolars. J Nerv Ment Dis 173:42-50, 1985

Pearlson GD, Kim WS, Kubos KL, et al: Ventricle-brain ratio, computed tomographic density and brain area in 50 schizophrenics. Arch Gen Psychiatry 46:690-697, 1989

Peralta V, Cuesta MJ, De Leon J. Positive and negative symptoms/syndromes in schizophrenia: Reliability and validity of different diagnostic systems. Psychological Medicine 25:43-50, 1995

Perry PJ, Miller DD, Arndt SV, et al: C10zapine and norclozapine plasma concentrations and clinical response of treatment-refractory schizophrenic patients. Am J Psychiatry 148:231-235,1991

Perry PJ, Pfohl BM, Kelley MW: The relationship of haloperidol concentrations to

therapeutic response. J Clin Psychopharmacol 8:38-43, 1988 Perry PJ. Clinical use of the newer antipsychotic drugs. American Journal of Hospital

Pharmacy 52 Suppl. 1 :S9-S 14, 1995 Peuskens J. Peer review of "Risperidone in the treatment of patients with chronic

schizophrenia: A multi-national, multi-centre, double-blind, parallel-group study versus haloperidol". Response. British Journal of Psychiatry 166:731-733. 1995

Peuskens J. Risperidone in the treatment of patients with chronic schizophrenia: A multi­national, multi-centre, double-blind, parallel-group study versus haloperidol. British Journal of Psychiatry 166:712-726, 1995

Pfohl B, Winokur G: The micro psychopathology of hebephrenic! catatonic schizophrenia. J Nerv Ment Dis 171 :296-300, 1983

154

Lirerarur

Pickar D, Hsiao JK. Clozapine treatment of schizophrenia. Journal of the American Medical Association 274:981-983, 1995

Propping P, Friedl W: Genetic studies of biochemical, pathophysiological, and pharmacological factors in schizophrenia, in Handbook of Schizophrenia, Vol III: Nosology, Epidemiology, and Genetics of Schizophrenia. Edited by Tsuang MT, Simpson Jc. Amsterdam, Elsevier, 1988, pp 579-608

Propping P, Nothen MM. Schizophrenia: Genetic tools for unraveling the nature of a complex disorder. Proceedings of the National Academy of Sciences of the United States of America 92:7607-7608, 1995

Provencher HL, Mueser KT. Positive and negative symptom behaviors and caregiver burden in the relatives of persons with schizophrenia. Schizophr Res 26:71-80, 1997

Pulver AE, Brown CH, Wolyniec PS, et al: Psychiatric morbidity in the relatives of patients with DSM-III schizophreniform disorder: comparisons with the relatives of schizophrenic and bipolar patients. J Psychiatr Res 25: 19-29, 1991

Quitkin F, Rifkin A, Klein DF: Neurologic soft signs in schizophrenia and character disorders: organicity in schizophrenia with premorbid asociality and emotionally unstable character disorders. Arch Gen Psychiatry 33:845-853, 1976

Rantakallio P, Jones P, Moring J, Von Wendt L. Association between central nervous system infections during childhood and adult onset schizophrenia and other psychoses: A 28-year follow-up. Int J Epidemiol 26:837-843, 1997

Rao ML, Strebel B, Halaris A, et al. Circadian rhythm of vital signs, norepinephrine, epinephrine, thyroid hormones, and cortisol in schizophrenia. Psychiatry Research 57:21-39, 1995

Rapoport JL, Giedd J, Kumra S, et al. Childhood-onset schizophrenia - Progressive ventricular change during adolescence. Arch Gen Psychiatry 54:897-903, 1997

Regier DA, Myers JK, Kramer M, et al: The NIMH Epidemiologic Catchment Area Pro­gram: historical context, major objectives, and study population characteristics. Arch Gen Psychiatry 41 :934-941, 1984

Reynolds GP. What is an atypical antipsychotic? J Psychopharmacol 11:195-199, 1997 Riecher-Rossler A, Rossler W, Forst! H, Meise U. Late-onset schizophrenia and late

paraphrenia. Schizophr Bull 21 :345-354, 1995 Robins LN, Helzer JE, Weissman MM, et al: Lifetime prevalence of specific psychiatric

disorders in three sites. Arch Gen Psychiatry 41 :949-958, 1984 Roder V, Jenull B, Brenner HD, Heimberg D, Hirsbrunner A. Cognitive behaviour

therapy with schizophrenic patients in the areas of living, work and leisure time: First results. Verhaltenstherapie 5:68-80, 1995

Roder V, Keppeler U, Jenull B, Brenner HD. Behaviour therapy with schizophrenic patients in the area ofleisure time: Case report. Verhaltenstherapie 5:96-99, 1995

Rosenheck R, Cramer J, Xu WC, et al. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. N Engl J Med 337:809-815, 1997

Rossau CD, Mortensen PB. Risk factors for suicide in patients with schizophrenia: nested case-control study. Br J Psychiatry 171 :355-359, 1997

155

Literatur

Rosse RB, Kendrick K, Tsui LC, et al. Famotidine adjunctive pharmacotherapy of schizophrenia: A case report. Clinical Neuropharmacology 18:369-374, 1995

Rossi A, Str~tta P, Casacchia M, et al: Reduced temporal lobe areas in schizophrenia: preliminary evidences from a controlled multiplanar magnetic resonance imaging study. Bioi Psychiatry 27:61-68, 1990

Roy A: Suicide in chronic schizophrenia. Br] Psychiatry 141 : 171-177, 1982 Rudin E: Studien tiber Vererbung und Entstehung geistiger Stotungen, I: Zur Vererbung

und Neuentstehung der Dementia Praecox. Berlin, Springer, 1916 Sartorius N, ]ablensky A, Korten A: Early manifestations and first contact incidence of

schizophrenia in different cultures: a preliminary report on the evaluation of the WHO Collaborative Study in Determinants of Outcome of Severe Mental Disorders. Psychol Med 16:909-928, 1986

SaG H, Wittchen H-U, Zaudig M. Diagnostisches und Statistisches Manual Psychischer Storungen DSM-IV. Hogrefe: Gottingen, Bern, Toronto, Seattle 1996

Schulsinger F, Parnas ], Petersen ET, et al: Cerebral ventricular size in the offspring of schizophrenic mothers: a preliminary study. Arch Gen Psychiatry 41 :602-606, 1984

SchwarzkopfSB, Nasrallah HA, Olson SC, et al: Family history and brain morphology in schizophrenia: an MRI study. Psychiatry Research: Neuroimaging 40:49-60, 1991

SchwarzkopfSB, Nasrallah HA, Olson SC, et al: Smaller MRI brain measures in familial vs sporadic schizophrenics: a replication. Schizophrenia Research 2: 128, 1989

Schwarzkopf SB, Olson SC, Nasrallah HA: Third and lateral ventricular volumes in schizophrenia: support for progress ive enlargement of both structures. Psychopharmacol Bull 26:385-391, 1990

Sedvall G, Farde L. Chemical brain anatomy in schizophrenia. Lancet 346:743-749, 1995 Seeman MV: Current outcome in schizophrenia: women vs men. Acta Psychiatr Scand

73:609-61 7, 1986 Seeman P, Van Tol HHM. D4 receptors and schizophrenia - Reply.] Neurochem 65:2382-

2383, 1995 Seidman L], Faraone Sv, Goldstein ]M, et al. Reduced subcortical brain volumes in

non psychotic siblings of schizophrenic patients: A pilot magnetic resonance imaging study. Am J Med Genet 74:507-514, 1997

Serper MR, Alpert M, Richardson NA, Dickson S, Allen MH, Werner A. Clinical effects of recent cocaine use on patients with acute schizophrenia. American Journal of Psychiatry 152:1464-1 469, 1995

Shapiro S, Skinner EA, Kessler LG, et al: Utilization of health and mental health services: three Epidemiologic Catchment Area sites. Arch Gen Psychiatry 41 :971-978, 1984

Sheitman BB, Lindgren JC, Early J, Sved M. High-dose olanzapine for treatment­refractory schizophrenia. Am J Psychiatry 154: 1626, 1997

Sherrington R, Brynjolfsson J, Peturssen H, et al: Localization of a susceptibiliry locus for schizophrenia on chromosome 5. Nature 336: 164-166, 1988

Siever LJ, Coursey RD, Alterman IS, et al: Impaired smooth pursuit eye movement: vulnerability marker for schizotypal personality disorder in a normal volunteer population. Am J Psychiatry 141: 1560-1566, 1984

156

Lirerarur

Silbersweig DA, Stern E, Frith C, et al. A functional neuroanatomy of hallucinations in schizophrenia. Nature 378:176-179,1995

Silver H, Kaplan A, Jahjah N. Fluvoxamine augmentation for dozapine-resistant schizophrenia. American Journal of Psychiatry 152: 1 098, 1995

Smythies J. Endogenous neurotoxins relevant to schizophrenia. J R Soc Med 89:679-680, 1996

Spitzer RL, Endicott J, Robins E: Research Diagnostic Criteria, 3rd Edition. New York, New York State Psychiatric Institute. Biometrics Research Division, 1978

Spitzer RL, Endicott J, Robins E: Research Diagnostic Criteria: rationale and reliability. Arch Gen Psychiatry 35:773-782,1978

Sramek]], Mack RJ, Awni W, et al. Two rapid-dose titrations of sertindole in patients with schizophrenia. J din Psychopharmacol 17:419-422, 1997

Stanton AH, Gunderson JG, Knapp PH, et al: Effects of psychotherapy in schizophrenia, I: design and implementation of a controlled study. Schizophr Bull 10:520-563, 1984

Startup M. Awareness of own and others' schizophrenic illness. Schizophr Res 26:203-211, 1997

Stefan MD, Murray RM. Schizophrenia: developmental disturbance of brain and mind? Acta Paediatr 86: 112-116, 1997

Stevens JR. Anatomy of schizophrenia revisited. Schizophr Bull 23:373-383, 1997 Stevens JR: Neurology and neuropathology of schizophrenia, in Schizophrenia as a Brain

Disease. Edited by Henn FA, Nasrallah HA. New York, Oxford University Press, 1982, pp 112-147

Stoudemire A: A differential diagnosis of catatonic states. Psychosomatics 23:245-251, 1982

Strange PG, Vile JM. D4 receptors and schizophrenia. J Neurochem 65:2381-2382, 1995 Strauss JS, Carpenter WT Jr: Schizophrenia. New York, Plenum, 1981 Suddath RC, Christison GW, Torrey EF, et al: Anatomical abnormalities in the brains of

monozygotic twins discordant for schizophrenia. N Engl J Med 322: 789-794, 1990 Suddath RL, Casanova MF, Goldberg TE, et al: Temporal lobe pathology in schizophrenia:

a quantitative magnetic resonance imaging study. Am J Psychiatry 146: 464-472, 1989

Swartz CM. Tardive psychopathology. Neuropsychobiology 32: 115-119, 1995 Swayze VW, Andreasen NC, Alliger RJ, et al: Subcortical and temporal structures in

affective disorder and schizophrenia: a magnetic resonance imaging study. BioI Psychiatry 31:221-240,1992

Takei N, Murray RM, Sham P, O'Callaghan E. Schizophrenia risk for women from in utero exposure to influenza. American Journal of Psychiatry 152: 150-151, 1995

Tanner TB, Ganguli R, Reddy R, Allen M, Field K. Risperidone for treatment-refractory schizophrenia. American Journal of Psychiatry 152: 1233, 1995

Taylor MA, Abrams R: Cognitive impairment in schizophrenia. Am J Psychiatry 141: 196-201, 1984

157

Literatur

Teplin LA: The criminality of the mentally ill: a dangerous misconception. Am J Psychiatry 142:593-599, 1985

Terao T, Oga T, Nozaki S, et al. Lithium addition to neuroleptic treatment in chronic schizophrenia: A randomized, double-blind, placebo-controlled, cross-over study. Acta Psychiatr Scand Acta-Psychiatrica-Sc:220-224, 1995

Tienari P: Psychiatric illness in identical twins. Acta Psychiatr Scand Suppl, No 171, 1963 Tollefson GD, Beasley CM,Jr., Tamura RN, Tran PV, Potvin JH. Blind, controlled, long­

term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol. Am J Psychiatry 154: 1248-1254, 1997

Tran PY, Hamilton SH, Kuntz AJ, et al. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J clin PsychopharmacoI17:407-418,1997

Trimble MR: First-rank symptoms of Schneider: a new perspective? Br J Psychiatry 156:195-200,1990

Tsuang MT, Simpson JC (eds): Handbook of Schizophrenia, Vol III: Nosology, Epidemiology, and Genetics of Schizophrenia. Amsterdam, Elsevier, 1988

Tsuang MT: Suicide in schizophrenics, manics, depressives, and surgical controls: a comparison with general population suicide mortality. Arch Gen Psychiatry 35:153-155,1978

Tsuang MT, Woolson RF, Winokur G, et al: Stability of psychiatric diagnosis: schizophrenia and affective disorders followed up over a 30- to 40-year period. Arch Gen Psychiatry 38:535-539,1981

Turner SW, Toone BK, Brett-Jones JR: Computerized tomographic scan change in early schizophrenia. Psychol Med 16:209-225, 1986

Vaillant GE: Prospective prediction of schizophrenic remission. Arch Gen Psychiatry 11:509-518,1964

Vallada HP, Gill M, Sham P, et al. Linkage studies on chromosome 22 in familial schizophrenia. American Journal of Medical Genetics 60: 139-146, 1995

Van Kammen DP, Kelley ME, Gurklis JA, Gilbertson MW; Yao JK, Peters JL. Behavioral vs biochemical prediction of clinical stability following haloperidol withdrawal in schizophrenia. Arch Gen Psychiatry Archives-of-General-:673-678, 1995

Van Putten T, Marder S, Mintz J: A controlled dose comparison of haloperidol in newly admitted schizophrenic patients. Arch Gen Psychiatry 47:754-758, 1990

Vartianinen H, Tiihonen J, Putkonen A, et al. Citalopram, a selective serotonin reuptake inhibitor, in the treatment of aggression in schizophrenia. Acta Psychiatr Scand Acta­Psychiatrica-Sc:348-351, 1995

Verdoux H, Magnin E, Bourgeois M. Neuroleptic effects on neuropsychological test performance in schizophrenia. Schizophrenia Research 14:133-139,1995

Vita A, Dieci M, Giobbio GM, et aI. Language and thought disorder in schizophrenia: Brain morphological correlates. Schizophrenia Research 15:243-251, 1995

Vita A, Sacchetti E. Developmental brain abnormalities in schizophrenia: Contributions of genetic and perinatal factors. Archives of General Psychiatry 52: 157, 1995

Vollema MG, Geurtsen GJ, Van Voorst AJP. Durable improvements in Wisconsin Card

158

Lirerarur

Sorting Test performance in schizophrenic patients. Schizophrenia Research 16:209-215,1995

Waddingron JL, O'Callaghan E, Buckley P, et al. Tardive dyskinesia in schizophrenia. Relationship ro minor physical anomalies, frontal lobe dysfunction and cerebral strucrure on magnetic resonance imaging. British Journal of Psychiarry 167: 41-44. 1995

Walker AM, Lanza LL, Arellano F, Rothman KJ. Mortality in current and former users of clozapine. Epidemiology 8:671-677, 1997

Wechsler 0: Wechsler Adult Intelligence Scale, Revised. New York, Psychological Corpo­ration, 1981

Weiden PJ, Olfson M. Cost of relapse in schizophrenia. Schizophr Bull 21 :419-429, 1995 Weinberger DR, Berman KF, Zec RF: Physiologic dysfunction of dorsolateral prefontal

cortex in schizophrenia, I: regional cerebral blood flow evidence. Arch Gen Psychiatry 43: 114-124, 1986

Weinberger DR, Bigelow LB, Kleinman JE, et al: Cerebral ventricular enlargement in chronic schizophrenia: an association with poor response ro treatment. Arch Gen Psychiatry 37:11-13,1980

Weinberger DR, Torrey EF, Neophytides AN, et al: Lateral cerebral ventricular enlargement in chronic schizophrenia. Arch Gen Psychiatry 36:735-739, 1979

Weinberger DR: Implications of normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatry 44:660-669, 1987

Wender PH, Rosenthal 0, Kety S5, et al: Social class and psychopathology in adoptees: a natural experimental method for separating the roles of genetic and experiential factors. Arch Gen Psychiatry 28:318-325, 1973

Wetzel H, Szegedi A, Hain C, Wiesner J, Schlegel S, Benkert O. Seroquel (ICI 204 636), a putative "atypical" antipsychotic, in schizophrenia with positive sympromarology: Results of an open clinical rrial and changes of neuroendocrinological and EEG parameters. Psychopharmacology 119:231-238.1995

White L, Harvey PO, Opler L, et al. Empirical assessment of the facrorial structure of clinical symptoms in schizophrenia - A multisite, mu1timodel evaluation of the facrorial structure of the Positive and Negative Syndrome Scale. Psychopathology 30:263-274. 1997

Wible CG, Shenton ME, Hokama H, et al. Prefrontal cortex and schizophrenia: A quanti tative magnetic resonance imaging srudy. Archives of General Psychiatry 52:279-288, 1995

Wi1coxJA, Nasrallah HA: Organic facrors in cataronia. Br J Psychiatry 149:782-784,1986 Wilcox JA, Nasrallah HA: Perinatal disrress and prognoSlS of psychotic illness.

Neuropsychobiology 17: 173-175, 1987 Wilson WH. Do anticonvulsants hinder clozapine rreatment. Biological Psychiatry

37:132-133,1995 Wilson WHo Time required for initial improvement during clozapine treatment of

refractory schizophrenia. Am J Psychiarry 153:951-952, 1996

159

Literatur

Wing JK, Birley JLT, Cooper JE, et al: Reliability of a procedure for measuring and classifying "present psychiatric state." Br J Psychiatry 113:499-515, 1967

Wolkowitz OM, Pickar D : Benzodiazepines in the treatment of schizophrenia: a review and reappraisal. Am J Psychiatry 148:714-726, 1991

Wong DF, Wagner HN, Tune LE, et al: Positron emission tomography reveals elevated D2 dopamine receptors in drug-naive schizophrenics. Science 234: 1558-1563, 1986

World Health Organization: International Statistical Classification of Diseases and Related Health Problems, 10th Revision (ICD-lO). Geneva, World Health Organization, 1992

Wyatt RJ. Early intervention for schizophrenia: Can the course of the illness be altered? Biological Psychiatry 38: 1-3, 1995

Wyatt RJ: Neuroleptics and the natural course of schizophrenia. Schizophr Bull 17:325-351,1991

Yalom ID: Inpatient Group Psychotherapy, New York, Basic Books, 1983 Yolken RH, Torrey EF. Viruses, schizophrenia, and bipolar disorder. Clinical Microbiology

Reviews 8:131-145,1995 Zipursky RB, Seeman MV, Bury A, Langevin R, Wortzman G, Katz R. Deficits in gray

matter volume are present in schizophrenia but not bipolar disorder. Schizophr Res 26:85-92, 1997

160